Cristina Tassorelli

List of Publications by Year
in descending order

353	12,869	30070 54	42399 92
papers	citations	h-index	g-index

359	359	359	11108
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology, 2012, 19, 703-711.	3.3	537
2	Functional changes of the basal ganglia circuitry in Parkinson's disease. Progress in Neurobiology, 2000, 62, 63-88.	5.7	477
3	Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes. Neurology, 2005, 65, 87-95.	1.1	323
4	ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology, 2007, 68, 1557-1562.	1.1	312
5	The impact of headache in Europe: principal results of the Eurolight project. Journal of Headache and Pain, 2014, 15, 31.	6.0	267
6	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia, 2018, 38, 815-832.	3.9	245
7	Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Research, 1995, 682, 167-181.	2.2	224
8	Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Movement Disorders, 2005, 20, 1439-1448.	3.9	219
9	Noninvasive vagus nerve stimulation as acute therapy for migraine. Neurology, 2018, 91, e364-e373.	1.1	186
10	Rational modulation of the innate immune system for neuroprotection in ischemic stroke. Frontiers in Neuroscience, 2015, 9, 147.	2.8	168
11	Cluster Headache Course Over Ten Years in 189 Patients. Cephalalgia, 1991, 11, 169-174.	3.9	154
12	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia, 2019, 39, 687-710.	3.9	154
13	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. European Journal of Human Genetics, 2006, 14, 322-331.	2.8	152
14	Headache, depression and anxiety: associations in the Eurolight project. Journal of Headache and Pain, 2016, 17, 59.	6.0	145
15	Cerebellar ataxia, neuropathy, vestibular areflexia syndrome due to RFC1 repeat expansion. Brain, 2020, 143, 480-490.	7.6	140
16	Migraine: integrated approaches to clinical management and emerging treatments. Lancet, The, 2021, 397, 1505-1518.	13.7	139
17	Italian guidelines for primary headaches: 2012 revised version. Journal of Headache and Pain, 2012, 13, 31-70.	6.0	129
18	Reliability of the Nitroglycerin Provocative Test in the Diagnosis of Neurovascular Headaches. Cephalalgia, 2004, 24, 110-119.	3.9	127

#	Article	IF	Citations
19	Immersive Virtual Reality and Virtual Embodiment for Pain Relief. Frontiers in Human Neuroscience, 2019, 13, 279.	2.0	125
20	Early rehabilitation after surgery improves functional outcome in inpatients with brain tumours. Journal of Neuro-Oncology, 2012, 107, 537-544.	2.9	112
21	Animal models of migraine: looking at the component parts of a complex disorder. European Journal of Neuroscience, 2006, 24, 1517-1534.	2.6	110
22	A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia, 2014, 34, 645-655.	3.9	108
23	Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia, 2014, 34, 426-433.	3.9	106
24	Clinical features of migraine aura: Results from a prospective diary-aided study. Cephalalgia, 2017, 37, 979-989.	3.9	105
25	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia, 2020, 40, 1026-1044.	3.9	105
26	Botulinum toxin and neuromotor rehabilitation: An integrated approach to idiopathic cervical dystonia. Movement Disorders, 2006, 21, 2240-2243.	3.9	103
27	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurology, The, 2018, 17, 597-608.	10.2	101
28	Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. Journal of Headache and Pain, 2011, 12, 427-433.	6.0	100
29	Nitroglycerin induces hyperalgesia in ratsâ€"a time-course study. European Journal of Pharmacology, 2003, 464, 159-162.	3.5	98
30	Interictal burden attributable to episodic headache: findings from the Eurolight project. Journal of Headache and Pain, 2016, 17, 9.	6.0	92
31	Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes. Neurology, 2007, 68, 583-589.	1.1	85
32	The effects on the central nervous system of nitroglycerinâ€"putative mechanisms and mediators. Progress in Neurobiology, 1999, 57, 607-624.	5.7	81
33	An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 54-60.	1.9	81
34	Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype. Experimental Neurology, 2016, 275, 116-125.	4.1	81
35	Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine. Neuroscience Letters, 2002, 317, 135-138.	2.1	77
36	Disordered pupil reactivity in Parkinson's disease. Clinical Autonomic Research, 1991, 1, 55-58.	2.5	76

#	Article	IF	Citations
37	Parthenolide is the Component of Tanacetum Parthenium that Inhibits Nitroglycerin-Induced Fos Activation: Studies in an Animal Model of Migraine. Cephalalgia, 2005, 25, 612-621.	3.9	76
38	Nitroglycerin as a comparative experimental model of migraine pain: From animal to human and back. Progress in Neurobiology, 2019, 177, 15-32.	5.7	76
39	Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. Neuroscience Letters, 2009, 467, 203-207.	2.1	75
40	Pisa syndrome in Parkinson's disease: Clinical, electromyographic, and radiological characterization. Movement Disorders, 2012, 27, 227-235.	3.9	75
41	Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action. Neurotherapeutics, 2018, 15, 313-323.	4.4	73
42	European Academy of Neurology guideline on the management of medicationâ€overuse headache. European Journal of Neurology, 2020, 27, 1102-1116.	3.3	69
43	Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. Journal of Headache and Pain, 2013, 14, 10.	6.0	68
44	Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. Autonomic Neuroscience: Basic and Clinical, 2012, 169, 77-86.	2.8	65
45	Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia, 2014, 34, 594-604.	3.9	64
46	Neuropathological findings from COVIDâ€19 patients with neurological symptoms argue against a direct brain invasion of SARSâ€CoVâ€2: A critical systematic review. European Journal of Neurology, 2021, 28, 3856-3865.	3.3	64
47	NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration. Brain Research, 1995, 695, 37-44.	2.2	63
48	Effects of acute and chronic restraint stress on nitroglycerin-induced hyperalgesia in rats. Neuroscience Letters, 2005, 383, 7-11.	2.1	63
49	Peripheral Levels of BDNF and NGF in Primary Headaches. Cephalalgia, 2006, 26, 136-142.	3.9	63
50	Fourâ€week trunkâ€specific rehabilitation treatment improves lateral trunk flexion in Parkinson's disease. Movement Disorders, 2010, 25, 325-331.	3.9	62
51	Reduced-Intensity Modified Constraint-Induced Movement Therapy Versus Conventional Therapy for Upper Extremity Rehabilitation After Stroke. Neurorehabilitation and Neural Repair, 2012, 26, 1035-1045.	2.9	60
52	Changes in Nociceptive Flexion Reflex Threshold Across the Menstrual Cycle in Healthy Women. Psychosomatic Medicine, 2002, 64, 621-626.	2.0	60
53	Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson?s disease. The effect of dopaminergic treatment. Journal of Neural Transmission, 2004, 111, 1017-30.	2.8	58
54	The endocannabinoid system and migraine. Experimental Neurology, 2010, 224, 85-91.	4.1	58

#	Article	IF	Citations
55	Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia, 2008, 28, 114-26.	3.9	58
56	A basic diagnostic headache diary (BDHD) is well accepted and useful in the diagnosis of headache. A multicentre European and Latin American study. Cephalalgia, 2011, 31, 1549-1560.	3.9	56
57	Spinal Autophagy is Differently Modulated in Distinct Mouse Models of Neuropathic Pain. Molecular Pain, 2015, 11, 1744-8069-11-3.	2.1	54
58	Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. Cephalalgia, 2010, 30, 296-302.	3.9	52
59	Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception, 2013, 88, 369-375.	1.5	52
60	Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17Î²â€estradiol. FEBS Journal, 2007, 274, 4464-4775.	4.7	51
61	Facilitated temporal summation of pain at spinal level in Parkinson's disease. Movement Disorders, 2011, 26, 442-448.	3.9	51
62	Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: A placebo controlled study. Parkinsonism and Related Disorders, 2014, 20, 1140-1144.	2.2	51
63	Effects of peripheral FAAH blockade on NTG-induced hyperalgesiaâ€"evaluation of URB937 in an animal model of migraine. Cephalalgia, 2015, 35, 1065-1076.	3.9	50
64	The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model. Journal of Headache and Pain, 2017, 18, 94.	6.0	50
65	Activation of the Transcription Factor NF-ÎºB in the Nucleus Trigeminalis Caudalis in an Animal Model of Migraine. NeuroToxicology, 2005, 26, 795-800.	3.0	49
66	Homocysteine and Parkinson's disease: A dangerous liaison?. Journal of the Neurological Sciences, 2007, 257, 31-37.	0.6	49
67	Acute Reduction of Anandamideâ€Hydrolase (FAAH) Activity is Coupled With a Reduction of Nociceptive Pathways Facilitation in Medicationâ€Overuse Headache Subjects After Withdrawal Treatment. Headache, 2012, 52, 1350-1361.	3.9	49
68	Intracerebral vascular changes induced by cold pressor test: A model of sympathetic activation. Neurological Research, 1994, 16, 163-167.	1.3	48
69	Pupillary and cardiovascular responses to the cold-pressor test. Journal of the Autonomic Nervous System, 1995, 55, 45-49.	1.9	48
70	Impact of headache disorders in Italy and the public-health and policy implications: a population-based study within the Eurolight Project. Journal of Headache and Pain, 2015, 16, 100.	6.0	48
71	Migraine aura symptoms: Duration, succession and temporal relationship to headache. Cephalalgia, 2016, 36, 413-421.	3.9	48
72	The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia, 2017, 37, 1115-1125.	3.9	48

#	Article	IF	Citations
73	Endocannabinoid System and Migraine Pain: An Update. Frontiers in Neuroscience, 2018, 12, 172.	2.8	48
74	Modulation of proâ€survival and deathâ€associated pathways under retinal ischemia/reperfusion: effects of NMDA receptor blockade. Journal of Neurochemistry, 2008, 107, 1347-1357.	3.9	47
75	Medication Overuse Headache and Applicability of the ICHD-II Diagnostic Criteria: 1-Year Follow-Up Study (CARE I Protocol). Cephalalgia, 2009, 29, 233-243.	3.9	47
76	Diagnostic and therapeutic errors in trigeminal autonomic cephalalgias and hemicrania continua: a systematic review. Journal of Headache and Pain, 2013, 14, 14.	6.0	47
77	Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. European Journal of Neurology, 2020, 27, 536-541.	3.3	47
78	Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurological Sciences, 2008, 29, 360-363.	1.9	46
79	COVIDâ€19: what if the brain had a role in causing the deaths?. European Journal of Neurology, 2020, 27, e41-e42.	3.3	46
80	Neurochemical mechanisms of nitroglycerin-induced neuronal activation in rat brain: A pharmacological investigation. Neuropharmacology, 1997, 36, 1417-1424.	4.1	45
81	Neuroprotection by leptin in a rat model of permanent cerebral ischemia: effects on STAT3 phosphorylation in discrete cells of the brain. Cell Death and Disease, 2011, 2, e238-e238.	6.3	45
82	An Opposite-Direction Modulation of the COMT Val158Met Polymorphism on the Clinical Response to Intrathecal Morphine and Triptans. Journal of Pain, 2013, 14, 1097-1106.	1.4	45
83	The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. Journal of Headache and Pain, 2011, 12, 541-549.	6.0	44
84	Role of D-Limonene in Autophagy Induced by Bergamot Essential Oil in SH-SY5Y Neuroblastoma Cells. PLoS ONE, 2014, 9, e113682.	2.5	44
85	Chronic and intermittent administration of systemic nitroglycerin in the rat induces an increase in the gene expression of CGRP in central areas: potential contribution to pain processing. Journal of Headache and Pain, 2018, 19, 51.	6.0	42
86	Variability of the characteristics of a migraine attack within patients. Cephalalgia, 2016, 36, 825-830.	3.9	41
87	Cognitive Telerehabilitation for Older Adults With Neurodegenerative Diseases in the COVID-19 Era: A Perspective Study. Frontiers in Neurology, 2020, 11, 623933.	2.4	41
88	Prostaglandins, glutamate and nitric oxide synthase mediate nitroglycerin-induced hyperalgesia in the formalin test. European Journal of Pharmacology, 2006, 534, 103-107.	3.5	40
89	Effect of Sex and Estrogens on Neuronal Activation in an Animal Model of Migraine. Headache, 2013, 53, 288-296.	3.9	39
90	Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms. Cephalalgia, 2017, 37, 1272-1284.	3.9	39

#	Article	IF	Citations
91	Telemedicine and Virtual Reality at Time of COVID-19 Pandemic: An Overview for Future Perspectives in Neurorehabilitation. Frontiers in Neurology, 2021, 12, 646902.	2.4	39
92	Development and validation of the EUROLIGHT questionnaire to evaluate the burden of primary headache disorders in Europe. Cephalalgia, 2010, 30, 1082-1100.	3.9	38
93	Effects of anandamide in migraine: data from an animal model. Journal of Headache and Pain, 2011, 12, 177-183.	6.0	38
94	Pain in focal dystonias â€“ A focused review to address an important component of the disease. Parkinsonism and Related Disorders, 2018, 54, 17-24.	2.2	38
95	Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. Journal of Headache and Pain, 2017, 18, 38.	6.0	37
96	Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization. Pain and Therapy, 2021, 10, 287-314.	3.2	37
97	Peripheral and Central Activation of Trigeminal Pain Pathways in Migraine: Data From Experimental Animal Models. Cephalalgia, 2003, 23, 1-4.	3.9	36
98	A Role for Brain Cyclooxygenaseâ€2 and Prostaglandinâ€E2 in Migraine: Effects of Nitroglycerin. International Review of Neurobiology, 2007, 82, 373-382.	2.0	36
99	Reduced Habituation of Trigeminal Reflexes in Patients with Episodic Cluster Headache During Cluster Period. Cephalalgia, 2008, 28, 950-959.	3.9	36
100	Temporal profile of vascular changes induced by systemic nitroglycerin in the meningeal and cortical districts. Cephalalgia, 2011, 31, 190-198.	3.9	36
101	Botulinum Toxin Is Effective in the Management of Neurogenic Dysphagia. Clinical-Electrophysiological Findings and Tips on Safety in Different Neurological Disorders. Frontiers in Pharmacology, 2017, 8, 80.	3.5	36
102	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition. Cephalalgia, 2019, 39, 803-816.	3.9	36
103	The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. European Journal of Pharmacology, 2010, 641, 82-87.	3.5	35
104	Illicit drug use in cluster headache patients and in the general population: A comparative cross-sectional survey. Cephalalgia, 2012, 32, 1031-1040.	3.9	35
105	Estimation of human trunk movements by wearable strain sensors and improvement of sensorâ€™s placement on intelligent biomedical clothes. BioMedical Engineering OnLine, 2012, 11, 95.	2.7	35
106	Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. Brain Research, 2007, 1176, 53-61.	2.2	34
107	Oral nitric-oxide donor glyceryl-trinitrate induces sensitization in spinal cord pain processing in migraineurs: A double-blind, placebo-controlled, cross-over study. European Journal of Pain, 2011, 15, 482-490.	2.8	34
108	Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. Journal of Headache and Pain, 2016, 17, 20.	6.0	34

#	Article	IF	Citations
109	Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 101.	6.0	34
110	Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke. Current Medicinal Chemistry, 2014, 21, 2098-2117.	2.4	34
111	Factors associated with a negative outcome of medication-overuse headache: A 3-year follow-up (the) Tj ETQq1 1 0.784314 rgBT /Ove	3.9	33
112	Nonparalytic botulinum molecules for the control of pain. Pain, 2016, 157, 1045-1055.	4.2	33
113	FAAH inhibition as a preventive treatment for migraine: A pre-clinical study. Neurobiology of Disease, 2020, 134, 104624.	4.4	33
114	Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. Journal of Chemical Neuroanatomy, 2004, 27, 23-32.	2.1	32
115	The Usefulness and Applicability of a Basic Headache Diary Before First Consultation: Results of a Pilot Study Conducted In Two Centres. Cephalalgia, 2008, 28, 1023-1030.	3.9	32
116	Identification of distinct cellular pools of interleukin-1Î² during the evolution of the neuroinflammatory response induced by transient middle cerebral artery occlusion in the brain of rat. Brain Research, 2010, 1313, 259-269.	2.2	32
117	Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy. Journal of Headache and Pain, 2015, 16, 532.	6.0	32
118	Antagonism of Transient Receptor Potential Ankyrin Type-1 Channels as a Potential Target for the Treatment of Trigeminal Neuropathic Pain: Study in an Animal Model. International Journal of Molecular Sciences, 2018, 19, 3320.	4.1	32
119	Central Components of the Analgesic/Antihyperalgesic Effect of Nimesulide. Drugs, 2003, 63, 9-22.	10.9	31
120	Evaluation of ADMA-DDAH-NOS axis in specific brain areas following nitroglycerin administration: study in an animal model of migraine. Journal of Headache and Pain, 2015, 16, 560.	6.0	31
121	Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Doubleâ€Blind Placeboâ€Controlled Phase 3 Clinical Studies. Headache, 2019, 59, 1788-1801.	3.9	31
122	Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. Journal of Headache and Pain, 2021, 22, 114.	6.0	31
123	Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. Journal of Headache and Pain, 2014, 15, 14.	6.0	30
124	Clinical and Demographical Characteristics of Patients with Medication Overuse Headache in Argentina and Chile: Analysis of the Latin American Section of COMOESTAS Project. Journal of Headache and Pain, 2015, 16, 83.	6.0	30
125	Traumatic Experiences, Stressful Events, and Alexithymia in Chronic Migraine With Medication Overuse. Frontiers in Psychology, 2018, 9, 704.	2.1	30
126	Effects of nimesulide on nitric oxide-induced hyperalgesia in humansâ€”a neurophysiological study. European Journal of Pharmacology, 2002, 450, 259-262.	3.5	29

#	Article	IF	Citations
127	Nitroglycerin-Induced Activation of Monoaminergic Transmission in the Rat. Cephalalgia, 2002, 22, 226-232.	3.9	29
128	Economic benefits of treating medication-overuse headache â€“ results from the multicenter COMOESTAS project. Cephalalgia, 2019, 39, 274-285.	3.9	29
129	Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine. Neurobiology of Disease, 2021, 147, 105157.	4.4	29
130	Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia, 2022, 42, 3-11.	3.9	29
131	Machine Learning Approach to Support the Detection of Parkinsonâ€™s Disease in IMU-Based Gait Analysis. Sensors, 2022, 22, 3700.	3.8	29
132	Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia. Brain Research, 2008, 1238, 215-223.	2.2	28
133	Chapter 28 Identification of Novel Pharmacological Targets to Minimize Excitotoxic Retinal Damage. International Review of Neurobiology, 2009, 85, 407-423.	2.0	28
134	What do the patients with medication overuse headache expect from treatment and what are the preferred sources of information?. Journal of Headache and Pain, 2011, 12, 91-96.	6.0	28
135	Psychological factors associated with failure of detoxification treatment in chronic headache associated with medication overuse. Cephalalgia, 2016, 36, 1356-1365.	3.9	28
136	When cervical pain is actually migraine: An observational study in 207 patients. Cephalalgia, 2018, 38, 383-388.	3.9	28
137	A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache. Cephalalgia, 2018, 38, 1361-1373.	3.9	28
138	Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?. Journal of Headache and Pain, 2020, 21, 122.	6.0	28
139	Role of Estrogens in Menstrual Migraine. Cells, 2022, 11, 1355.	4.1	28
140	Long-Term Evaluation of the Effect of Quetiapine on Hallucinations, Delusions and Motor Function in Advanced Parkinson Disease. Clinical Neuropharmacology, 2004, 27, 33-37.	0.7	27
141	Differences in the Personality Profile of Medication-Overuse Headache Sufferers and Drug Addict Patients: A Comparative Study Using MMPI-2. Headache, 2011, 51, 1212-1227.	3.9	27
142	Early reperfusion injury is associated to MMP2 and IL-1Î² elevation in cortical neurons of rats subjected to middle cerebral artery occlusion. Neuroscience, 2014, 277, 755-763.	2.3	27
143	Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. Journal of Headache and Pain, 2017, 18, 66.	6.0	27
144	Smart Aging Platform for Evaluating Cognitive Functions in Aging: A Comparison with the MoCA in a Normal Population. Frontiers in Aging Neuroscience, 2017, 9, 379.	3.4	27

#	Article	IF	Citations
145	Factors associated to chronic migraine with medication overuse: A cross-sectional study. Cephalalgia, 2018, 38, 2045-2057.	3.9	27
146	Gender Differences in the Clinical Presentation of Cluster Headache: A Role for Sexual Hormones?. Frontiers in Neurology, 2019, 10, 1220.	2.4	27
147	Focus on therapy of the Chapter IV headaches provoked by exertional factors: primary cough headache, primary exertional headache and primary headache associated with sexual activity. Journal of Headache and Pain, 2010, 11, 525-530.	6.0	26
148	Sexual Function and Distress in Women Treated for Primary Headaches in a Tertiary University Center. Journal of Sexual Medicine, 2012, 9, 761-769.	0.6	26
149	Alexithymia in chronic and episodic migraine: a comparative study. Journal of Mental Health, 2017, 26, 192-196.	1.9	26
150	Non-invasive vagus nerve stimulation for primary headache: A clinical update. Cephalalgia, 2020, 40, 1370-1384.	3.9	26
151	Serious games for screening pre-dementia conditions: from virtuality to reality? A pilot project. Functional Neurology, 2014, 29, 153-8.	1.3	26
152	Pupil Responsiveness in Cluster Headache: A Dynamic TV Pupillometric Evaluation. Cephalalgia, 1988, 8, 193-201.	3.9	25
153	The role of rehabilitation in deep brain stimulation of the subthalamic nucleus for Parkinson's disease: A pilot study. Parkinsonism and Related Disorders, 2009, 15, 675-681.	2.2	25
154	An electronic diary on a palm device for headache monitoring: a preliminary experience. Journal of Headache and Pain, 2012, 13, 537-541.	6.0	25
155	In search of new targets for retinal neuroprotection: is there a role for autophagy?. Current Opinion in Pharmacology, 2013, 13, 72-77.	3.5	25
156	Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the COMOESTAS Project. Cephalalgia, 2019, 39, 135-147.	3.9	25
157	Proprioceptive Focal Stimulation (EquistasiÂ®) May Improve the Quality of Gait in Middle-Moderate Parkinson's Disease Patients. Double-Blind, Double-Dummy, Randomized, Crossover, Italian Multicentric Study. Frontiers in Neurology, 2019, 10, 998.	2.4	25
158	Effects of systemic administration of the essential oil of bergamot (BEO) on gross behaviour and EEG power spectra recorded from the rat hippocampus and cerebral cortex. Functional Neurology, 2009, 24, 107-12.	1.3	25
159	Imbalance of heart rate regulation in cluster headache as based on continuous 24-h recordings. Clinical Autonomic Research, 1993, 3, 291-298.	2.5	24
160	IkappaB-alpha expression following transient focal cerebral ischemia is modulated by nitric oxide. Brain Research, 2011, 1372, 145-151.	2.2	24
161	The Headache Under-Response to Treatment (HURT) Questionnaire: Assessment of utility in headache specialist care. Cephalalgia, 2013, 33, 245-255.	3.9	24
162	Functional polymorphisms in <scp>COMT</scp> and <scp>SLC</scp>6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. European Journal of Neurology, 2014, 21, 989-995.	3.3	24

#	Article	IF	Citations
163	Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics, 2018, 18, 167-176.	2.8	24
164	A computer-based cognitive training in Mild Cognitive Impairment in Parkinsonâ€™s Disease. NeuroRehabilitation, 2019, 44, 555-567.	1.3	24
165	The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment. Frontiers in Human Neuroscience, 2019, 13, 31.	2.0	24
166	Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. Cephalalgia, 2021, 41, 279-293.	3.9	24
167	Selective stimulation of striatal dopamine receptors of the D1- or D2-class causes opposite changes of fos expression in the rat cerebral cortex. European Journal of Neuroscience, 2003, 17, 763-770.	2.6	23
168	Experimental models of migraine. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 109-123.	1.8	23
169	The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. Journal of Headache and Pain, 2018, 19, 15.	6.0	23
170	Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemiaâ€reperfusion injury. Journal of Neuroscience Research, 2018, 96, 151-159.	2.9	23
171	Anodal transcranial direct current stimulation in chronic migraine and medication overuse headache: A pilot double-blind randomized sham-controlled trial. Clinical Neurophysiology, 2021, 132, 126-136.	1.5	23
172	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. Journal of Neurology, 2022, 269, 1335-1352.	3.6	23
173	Consensus on the treatment of dysphagia in Parkinson's disease. Journal of the Neurological Sciences, 2021, 430, 120008.	0.6	23
174	Assessing and treating primary headaches and cranio-facial pain in patients undergoing rehabilitation for neurological diseases. Journal of Headache and Pain, 2017, 18, 99.	6.0	22
175	Profiling the Biochemical Signature of GBAâ€Related Parkinson's Disease in Peripheral Blood Mononuclear Cells. Movement Disorders, 2021, 36, 1267-1272.	3.9	22
176	Cardiovascular dysautonomia as a cause of falls in Parkinson's disease. Parkinsonism and Related Disorders, 2006, 12, 195-204.	2.2	21
177	Neuroprotective Effect of Nitroglycerin in a Rodent Model of Ischemic Stroke: Evaluation of Bclâ€2 Expression. International Review of Neurobiology, 2007, 82, 423-435.	2.0	21
178	Focus on therapy: hemicrania continua and new daily persistent headache. Journal of Headache and Pain, 2010, 11, 259-265.	6.0	21
179	Comparative analysis of the neuronal activation and cardiovascular effects of nitroglycerin, sodium nitroprusside and l-arginine. Brain Research, 2005, 1051, 17-24.	2.2	20
180	Use of complementary and alternative medicine by patients with cluster headache: Results of a multi-centre headache clinic survey. Complementary Therapies in Medicine, 2008, 16, 220-227.	2.7	20

#	Article	IF	Citations
181	Focus on therapy of hypnic headache. Journal of Headache and Pain, 2010, 11, 349-354.	6.0	20
182	Prolonged migraine aura: new insights from a prospective diary-aided study. Journal of Headache and Pain, 2018, 19, 77.	6.0	20
183	5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. European Journal of Pharmacology, 2008, 580, 43-47.	3.5	19
184	Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. European Journal of Pharmacology, 2014, 744, 91-97.	3.5	19
185	Triptan use in Italy: Insights from administrative databases. Cephalalgia, 2015, 35, 619-626.	3.9	19
186	Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study. Journal of Headache and Pain, 2016, 17, 70.	6.0	19
187	Peripheral vagal nerve stimulation modulates the nociceptive withdrawal reflex in healthy subjects: A randomized, cross-over, sham-controlled study. Cephalalgia, 2018, 38, 1658-1664.	3.9	19
188	The endocannabinoid system in migraine: from bench to pharmacy and back. Current Opinion in Neurology, 2019, 32, 405-412.	3.6	19
189	Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. Cephalalgia, 2021, 41, 1135-1151.	3.9	19
190	Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine. Cells, 2021, 10, 2543.	4.1	19
191	Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. European Journal of Clinical Pharmacology, 2014, 70, 1195-1202.	1.9	18
192	Access to care - an unmet need in headache management?. Journal of Headache and Pain, 2014, 15, 20.	6.0	18
193	Headache yesterday in Europe. Journal of Headache and Pain, 2014, 15, 33.	6.0	18
194	Association of <scp>RAMP</scp>1â€...<scp>rs</scp>7590387 With the Risk of Migraine Transformation Into Medication Overuse Headache. Headache, 2015, 55, 658-668.	3.9	18
195	Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project. Cephalalgia, 2018, 38, 646-654.	3.9	18
196	Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 98.	6.0	18
197	A double-blind randomized controlled trial of the efficacy of cognitive training delivered using two different methods in mild cognitive impairment in Parkinsonâ€™s disease: preliminary report of benefits associated with the use of a computerized tool. Aging Clinical and Experimental Research, 2021, 33, 1567-1575.	2.9	18
198	Anodal transcranial direct current stimulation and intermittent thetaâ€burst stimulation improve deglutition and swallowing reproducibility in elderly patients with dysphagia. Neurogastroenterology and Motility, 2020, 32, e13791.	3.0	18

#	Article	IF	Citations
199	Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study. Cephalalgia, 2021, 41, 185-196.	3.9	18
200	Nitric oxide-induced neuronal activation in the central nervous system as an animal model of migraine: mechanisms and mediators. Functional Neurology, 2001, 16, 69-76.	1.3	18
201	The contribution of trigemino-cervical reflexes in distinguishing progressive supranuclear palsy from multiple system atrophy. Clinical Neurophysiology, 2011, 122, 1812-1815.	1.5	17
202	Transdermal Hormonal Therapy in Perimenstrual Migraine: Why, When and How?. Current Pain and Headache Reports, 2012, 16, 467-473.	2.9	17
203	Modulation of RAGE Isoforms Expression in the Brain and Plasma of Rats Exposed to Transient Focal Cerebral Ischemia. Neurochemical Research, 2012, 37, 1508-1516.	3.3	17
204	Acute and Chronic Effect of Acoustic and Visual Cues on Gait Training in Parkinsonâ€™s Disease: A Randomized, Controlled Study. Parkinson's Disease, 2015, 2015, 1-9.	1.1	17
205	A pilot study on the efficacy of transcranial direct current stimulation applied to the pharyngeal motor cortex for dysphagia associated with brainstem involvement in multiple sclerosis. Clinical Neurophysiology, 2019, 130, 1017-1024.	1.5	17
206	Effectiveness of a Piroxicam Fast Dissolving Formulation Sublingually Administered in the Symptomatic Treatment of Migraine Without Aura. Headache, 1993, 33, 296-300.	3.9	16
207	Increased Cerebral Blood Flow Velocity Induced by Cold Pressor Test in Migraine: A Possible Basis for Pathogenesis?. Cephalalgia, 1995, 15, 494-498.	3.9	16
208	Intrastriatal injection of D1 or D2 dopamine agonists affects glucose utilization in both the direct and indirect pathways of the rat basal ganglia. Neuroscience Letters, 2001, 309, 161-164.	2.1	16
209	Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson?s disease. Neurological Sciences, 2003, 24, 157-158.	1.9	16
210	Role of 2 Common Variants of 5HT2A Gene in Medication Overuse Headache. Headache, 2010, 50, 1587-1596.	3.9	16
211	Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations. Neurogenetics, 2011, 12, 263-271.	1.4	16
212	Negative Short-Term Outcome of Detoxification Therapy in Chronic Migraine With Medication Overuse Headache: Role for Early Life Traumatic Experiences and Recent Stressful Events. Frontiers in Neurology, 2019, 10, 173.	2.4	16
213	Body Weight Support Combined With Treadmill in the Rehabilitation of Parkinsonian Gait: A Review of Literature and New Data From a Controlled Study. Frontiers in Neurology, 2018, 9, 1066.	2.4	16
214	Uncommon primary headaches. Current Opinion in Neurology, 2006, 19, 299-304.	3.6	15
215	Focus on the management of thunderclap headache: from nosography to treatment. Journal of Headache and Pain, 2011, 12, 251-258.	6.0	15
216	Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism Impacts on Migraine Susceptibility: A Meta-analysis of Caseâ€“Control Studies. Frontiers in Neurology, 2017, 8, 159.	2.4	15

#	Article	IF	Citations
217	Personality and Personality Disorders in Medication-Overuse Headache: A Controlled Study by SWAP-200. Pain Research and Management, 2019, 2019, 1-9.	1.8	15
218	Clinical Subtypes of Medication Overuse Headache â€“ Findings From a Large Cohort. Headache, 2019, 59, 1481-1491.	3.9	15
219	Azithromycin Affords Neuroprotection in Rat Undergone Transient Focal Cerebral Ischemia. Frontiers in Neuroscience, 2019, 13, 1256.	2.8	15
220	High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients. Cephalalgia, 2021, 41, 1437-1446.	3.9	15
221	Lack of trigeminoâ€cervical reflexes in progressive supranuclear palsy. Movement Disorders, 2008, 23, 1475-1479.	3.9	14
222	Focus on therapy of primary stabbing headache. Journal of Headache and Pain, 2010, 11, 157-160.	6.0	14
223	Specific patterns of laryngeal electromyography during wakefulness are associated to sleep disordered breathing and nocturnal stridor in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 31, 104-109.	2.2	14
224	Mutations inTMEM230are not a common cause of Parkinson's disease. Movement Disorders, 2017, 32, 302-304.	3.9	14
225	Effect of Non-invasive Vagus Nerve Stimulation on Resting-State Electroencephalography and Laser-Evoked Potentials in Migraine Patients: Mechanistic Insights. Frontiers in Human Neuroscience, 2018, 12, 366.	2.0	14
226	What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Review of Neurotherapeutics, 2020, 20, 1275-1286.	2.8	14
227	Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study. Cephalalgia, 2020, 40, 1336-1345.	3.9	14
228	Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). Quality of Life Research, 2021, 30, 105-115.	3.1	14
229	The Smart Aging Platform for Assessing Early Phases of Cognitive Impairment in Patients With Neurodegenerative Diseases. Frontiers in Psychology, 2021, 12, 635410.	2.1	14
230	Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 841-854.	2.2	14
231	The endocannabinoid system and related lipids as potential targets for the treatment of migraineâ€related pain. Headache, 2022, 62, 227-240.	3.9	14
232	Sleep-apnoea and autonomic dysfunction: a cardiopressor and pupillometric study. Acta Neurologica Scandinavica, 1995, 91, 382-388.	2.1	13
233	Systemic nitroglycerin activates peptidergic and catecholaminergic pathways in rat brain. Peptides, 1996, 17, 443-449.	2.4	13
234	Characterization of CB2 Receptor Expression in Peripheral Blood Monocytes of Acute Ischemic Stroke Patients. Translational Stroke Research, 2021, 12, 550-558.	4.2	13

#	Article	IF	Citations
235	Ability of a Set of Trunk Inertial Indexes of Gait to Identify Gait Instability and Recurrent Fallers in Parkinsonâ€™s Disease. Sensors, 2021, 21, 3449.	3.8	13
236	Thalamocortical Connectivity in Experimentally-Induced Migraine Attacks: A Pilot Study. Brain Sciences, 2021, 11, 165.	2.3	13
237	NF-Î°B transcription factor subunits in rat brain: Colocalization of p65 and Î±-MSH. Peptides, 1996, 17, 655-664.	2.4	12
238	Reciprocal circuits involved in nitroglycerin-induced neuronal activation of autonomic regions and pain pathways: a double immunolabeling and tract-tracing study. Brain Research, 1999, 842, 294-310.	2.2	12
239	Enhanced temporal pain processing in multiple system atrophy. Neuroscience Letters, 2013, 555, 203-208.	2.1	12
240	Inhibition of monoacylglycerol lipase: Another signalling pathway for potential therapeutic targets in migraine?. Cephalalgia, 2018, 38, 1138-1147.	3.9	12
241	Non-invasive Brain and Spinal Stimulation for Pain and Related Symptoms in Multiple Sclerosis: A Systematic Review. Frontiers in Neuroscience, 2020, 14, 547069.	2.8	12
242	Chronic migraine and Botulinum Toxin Type A: Where do paths cross?. Toxicon, 2020, 178, 69-76.	1.6	12
243	PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. Pain Management, 2021, 11, 647-654.	1.5	12
244	Combined evaluation of pupillary and cardiovascular responses to cold pressor test in cluster headache patients. Cephalalgia, 1998, 18, 668-674.	3.9	11
245	Association of haplotype combination of serotonin transporter gene polymorphisms with monthly headache days in MOH patients. European Journal of Neurology, 2012, 19, 69-75.	3.3	11
246	Pharmacogenomics of episodic migraine: time has come for a step forward. Pharmacogenomics, 2014, 15, 541-549.	1.3	11
247	Modulation of cerebral RAGE expression following nitric oxide synthase inhibition in rats subjected to focal cerebral ischemia. European Journal of Pharmacology, 2017, 800, 16-22.	3.5	11
248	Experimentally induced spinal nociceptive sensitization increases with migraine frequency: a single-blind controlled study. Pain, 2020, 161, 429-438.	4.2	11
249	CD163 as a Potential Biomarker of Monocyte Activation in Ischemic Stroke Patients. International Journal of Molecular Sciences, 2021, 22, 6712.	4.1	11
250	A double-blind randomized controlled trial combining cognitive training (CoRe) and neurostimulation (tDCS) in the early stages of cognitive impairment. Aging Clinical and Experimental Research, 2022, 34, 73-83.	2.9	11
251	A questionnaire on sleep and mental disorders in Parkinson's disease (QSMDPD): development and application of a new screening tool. Functional Neurology, 2004, 19, 83-99.	1.3	11
252	The trigemino-pupillary reflex: a model of sensory-vegetative integration. Journal of the Autonomic Nervous System, 1992, 41, 179-185.	1.9	10

#	Article	IF	Citations
253	Eletriptan. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1587-1598.	3.3	10
254	Lack of association between GRIA1 polymorphisms and haplotypes with migraine without aura or response to triptans. Neurological Sciences, 2014, 35, 421-427.	1.9	10
255	Acute effects of high-frequency microfocal Cortical excitability changes over time in progressive multiple sclerosis muscle. A double-blind study in healthy subjects. Functional Neurology, 2015, 30, 269-74.	1.3	10
256	Falls, fractures and bone density in Parkinson's diseaseÂâ€“ a cross-sectional study. International Journal of Neuroscience, 2017, 127, 299-304.	1.6	10
257	Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study. Clinical Neurophysiology, 2017, 128, 1978-1984.	1.5	10
258	Botulinum toxin A modifies nociceptive withdrawal reflex in subacute stroke patients. Brain and Behavior, 2018, 8, e01069.	2.2	10
259	Using a Genetic Risk Score Approach to Predict Headache Response to Triptans in Migraine Without Aura. Journal of Clinical Pharmacology, 2019, 59, 288-294.	2.0	10
260	Isolated bulbar palsy after SARS-CoV-2 infection. Lancet Neurology, The, 2021, 20, 169-170.	10.2	10
261	Headache, low back pain, other nociceptive and mixed pain conditions in neurorehabilitation. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 867-880.	2.2	10
262	The Trigemino-Pupillary Response in Cluster Headache. Cephalalgia, 1993, 13, 338-342.	3.9	9
263	Botulinum toxin for chronic migraine: Clinical trials and technical aspects. Toxicon, 2018, 147, 111-115.	1.6	9
264	OnabotulinumtoxinA Reduces Temporal Pain Processing at Spinal Level in Patients with Lower Limb Spasticity. Toxins, 2019, 11, 359.	3.4	9
265	Clinical and Electrophysiological Outcome Measures of Patients With Post-Infectious Neurological Syndromes Related to COVID-19 Treated With Intensive Neurorehabilitation. Frontiers in Neurology, 2021, 12, 643713.	2.4	9
266	Andrographis Paniculata shows anti-nociceptive effects in an animal model of sensory hypersensitivity associated with migraine. Functional Neurology, 2016, 31, 53-60.	1.3	9
267	Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review. Headache, 2022, 62, 453-472.	3.9	9
268	Bilateral Asymmetry of Cerebral Blood Velocity in Cluster Headache. Cephalalgia, 1994, 14, 346-351.	3.9	8
269	Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine. Neurotherapeutics, 2021, 18, 556-568.	4.4	8
270	Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks. Pain, 2021, 162, 2376-2385.	4.2	8

#	Article	IF	Citations
271	Evaluation of the efficacy of physical therapy on cognitive decline at 6-month follow-up in Parkinson disease patients with mild cognitive impairment: a randomized controlled trial. Aging Clinical and Experimental Research, 2021, 33, 3275-3284.	2.9	8
272	Validity of the Severity of Dependence Scale for detecting dependence behaviours in chronic migraine with medication overuse. Cephalalgia, 2022, 42, 209-217.	3.9	8
273	Secondary cervical dystonia in iatrogenic hypoparathyroidism associated with extensive brain calcifications. Functional Neurology, 2006, 21, 165-6.	1.3	8
274	Tele-healthcare in migraine medicine: from diagnosis to monitoring treatment outcomes. Expert Review of Neurotherapeutics, 2022, 22, 237-243.	2.8	8
275	HomeCoRe for Telerehabilitation in Mild or Major Neurocognitive Disorders: A Study Protocol for a Randomized Controlled Trial. Frontiers in Neurology, 2021, 12, 752830.	2.4	8
276	Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat. Brain Research, 2006, 1101, 145-150.	2.2	7
277	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. Journal of Headache and Pain, 2019, 20, 15.	6.0	7
278	Migraine neuroscience: from experimental models to target therapy. Neurological Sciences, 2020, 41, 351-361.	1.9	7
279	Gene polymorphism association studies in cluster headache: A field synopsis and systematic metaâ€analyses. Headache, 2021, 61, 1060-1076.	3.9	7
280	BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm. Cephalalgia, 2022, 42, 170-175.	3.9	7
281	Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process. Cephalalgia, 2022, 42, 1387-1396.	3.9	7
282	Getting closer to a cure for migraine. Nature Reviews Neurology, 2019, 15, 64-65.	10.1	6
283	Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study. Cephalalgia, 2021, 41, 197-202.	3.9	6
284	Lasmiditan: an additional therapeutic option for the acute treatment of migraine. Expert Review of Neurotherapeutics, 2021, 21, 491-502.	2.8	6
285	Effect of nitric oxide donors on the central nervous system--nitroglycerin studies in the rat. Functional Neurology, 2000, 15 Suppl 3, 19-27.	1.3	6
286	Expression of Selected microRNAs in Migraine: A New Class of Possible Biomarkers of Disease?. Processes, 2021, 9, 2199.	2.8	6
287	Implementation and evaluation of existing guidelines on the use of neurophysiological tests in non-acute migraine patients: a questionnaire survey of neurologists and primary care physicians. European Journal of Neurology, 2009, 16, 937-942.	3.3	5
288	Death in pain: peripheral nerve injury and spinal neurodegenerative mechanisms. Current Opinion in Pharmacology, 2012, 12, 49-54.	3.5	5

#	Article	IF	Citations
289	Electrical Stimulation of Injected Muscles to Boost Botulinum Toxin Effect on Spasticity: Rationale, Systematic Review and State of the Art. Toxins, 2021, 13, 303.	3.4	5
290	Electrokinesiographic Study of Oropharyngeal Swallowing in Neurogenic Dysphagia. Dysphagia, 2023, 38, 543-557.	1.8	5
291	Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1st edition. Cephalalgia, 2022, 42, 1099-1115.	3.9	5
292	Pharmacological properties of nimesulide. , 2005, , 133-244.		4
293	A prospective multicentre study to evaluate the consistency of the IHS diagnostic criteria, the usefulness of brain MRI for the diagnosis, follow-up and treatment management, and the outcome after high dosage 6-methylprednisolone therapy, in subjects with Tolosaâ€“Hunt syndrome. Journal of Headache and Pain, 2010, 11, 285-285.	6.0	4
294	P043. Hyperechogenicity of the periaqueductal gray in chronic migraine and episodic migraine as a potential marker of progressive dysfunction: preliminary results with transcranial sonography. Journal of Headache and Pain, 2015, 16, A61.	6.0	4
295	P008. Alexithymia and chronic migraine with medication overuse: what relationship?. Journal of Headache and Pain, 2015, 16, A150.	6.0	4
296	Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia, 2019, 39, 1058-1066.	3.9	4
297	Intranasal midazolam for treating acute respiratory crises in a woman with stiff person syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	4
298	Reproducibility and reaction time of swallowing as markers of dysphagia in parkinsonian syndromes. Clinical Neurophysiology, 2020, 131, 2200-2208.	1.5	4
299	Have the IHS Guidelines for controlled trials of acute treatment of migraine attacks been followed? Laying the ground for the 4th edition. Cephalalgia, 2020, 40, 778-787.	3.9	4
300	From DYMUS to DYPARK: Validation of a Screening Questionnaire for Dysphagia in Parkinsonâ€™s Disease. Dysphagia, 2022, 37, 824-830.	1.8	4
301	Non-Invasive Neuromodulation in the Rehabilitation of Pisa Syndrome in Parkinson's Disease: A Randomized Controlled Trial. Frontiers in Neurology, 2022, 13, 849820.	2.4	4
302	The Use of Diaries in the Management of Headache. , 2011, , 197-209.		3
303	Electronic pupillometry for investigating pupil reactivity to different exteroceptive stimuli: applications and limits. Functional Neurology, 1987, 2, 529-38.	1.3	3
304	Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study. Cephalalgia, 2022, , 033310242210937.	3.9	3
305	Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine. Journal of Headache and Pain, 2022, 23, .	6.0	3
306	Evidence for the Impairment of Sensory/Nociceptive Integrative Processes in Cluster Headache. The Trigeminal Reflex. Cephalalgia, 1991, 11, 242-243.	3.9	2

#	Article	IF	Citations
307	Experimental models for the study of cluster headache. Italian Journal of Neurological Sciences, 1999, 20, S21-S24.	0.1	2
308	Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. Neurological Sciences, 2002, 23, s57-s58.	1.9	2
309	O011. Patients with â€œprolonged auraâ€•do not show clinical or demographic differences from the patients with â€œtypical auraâ€• Journal of Headache and Pain, 2015, 16, A67.	6.0	2
310	Cues and Body-Weight-Supported (BWS) Gait Training in Parkinsonâ€™s Disease. Biosystems and Biorobotics, 2018, , 357-366.	0.3	2
311	Dissecting out migraine complexity through comprehensive analysis of allodynia. Brain, 2019, 142, 5-8.	7.6	2
312	The Effects of Intensive Neurorehabilitation on Sequence Effect in Parkinson's Disease Patients With and Without Freezing of Gait. Frontiers in Neurology, 2021, 12, 723468.	2.4	2
313	Pearls & Oy-sters: Marionette walk in Parkinson's disease: a rare dyskinetic-dystonic gait pattern complication improved by visual cueing. Neurology, 2022, , 10.1212/WNL.0000000000200714.	1.1	2
314	Effectiveness of Salmon Calcitonin Nasal Spray Preparation in the Treatment of â€˜Chronicâ€™ Headache Form. Cephalalgia, 1989, 9, 400-401.	3.9	1
315	The Role of PO2/PCO2 in Cluster Headache Pathogenesis: Perspectives of the Oxygen/Ozone Therapy. Cephalalgia, 1991, 11, 272-273.	3.9	1
316	Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat. Experimental Neurology, 2006, 200, 240-244.	4.1	1
317	Disability caused by medication-overuse headache can be considerably reduced by detoxification. Results from multinational COMOESTAS study. Journal of Headache and Pain, 2013, 14, .	6.0	1
318	Effects of URB937 on an animal model of migraine pain. Journal of Headache and Pain, 2013, 14, .	6.0	1
319	EHMTI-0111. Intra-variability of migraine attacks features. Journal of Headache and Pain, 2014, 15, .	6.0	1
320	O029. Lessons from the expert patients. Advice for the physician to improve the care of cluster headache patients. Journal of Headache and Pain, 2015, 16, A94.	6.0	1
321	O010. Migraine aura symptoms last for more than one hour in more than one quarter of patients: results from a prospective diary-aided study. Journal of Headache and Pain, 2015, 16, A65.	6.0	1
322	O012. Intra-variability of the characteristics of migraine attacks. Journal of Headache and Pain, 2015, 16, A70.	6.0	1
323	Endocannabinoids and migraine. , 2015, , 173-189.		1
324	Noninvasive peripheral vagal nerve stimulation prevents migraine aura: A case report. Cephalalgia Reports, 2019, 2, 251581631985560.	0.7	1

#	Article	IF	Citations
325	Animals Models for Trigeminal Autonomic Cephalalgias. Headache, 2020, , 103-115.	0.4	1
326	Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. Myâ€LIFE European Delphi survey. European Journal of Pain, 2021, 25, 2177-2189.	2.8	1
327	The contribution of the Italian residents in neurology to the COVID-19 crisis: admirable generosity but neurological training remains their priority. Neurological Sciences, 2021, 42, 4425-4431.	1.9	1
328	Headache in 2021: clinical, biological, and genetic advances. Lancet Neurology, The, 2022, 21, 6-8.	10.2	1
329	Facial expressions modulate pain perception in patients with chronic migraine. Cephalalgia, 2022, , 033310242210750.	3.9	1
330	EUROLIGHT project: impact of primary headache disorders from a population-based study conducted in Pavia. Journal of Headache and Pain, 2013, 14, .	6.0	0
331	The â€œcareâ€•protocol: the role of personality in a three-year follow-up study of medication overuse headache. Journal of Headache and Pain, 2013, 14, .	6.0	0
332	The â€œcareâ€•protocol: outcome of medication overuse headache in a three year follow-up study. Journal of Headache and Pain, 2013, 14, .	6.0	0
333	EHMTI-0045. The succession of aura and headache: a prospective diary-based study. Journal of Headache and Pain, 2014, 15, .	6.0	0
334	EHMTI-0141. URB937 as a potential therapeutic option for migraine: evaluation in animal model of migraine. Journal of Headache and Pain, 2014, 15, .	6.0	0
335	EHMTI-0043. Clinically-oriented stratified approach and patient-preference approach in the management of MOH â€“ a comparison between two strategies. Journal of Headache and Pain, 2014, 15, .	6.0	0
336	EHMTI-0147. Medication overuse headache and alexithymia: a controlled study. Journal of Headache and Pain, 2014, 15, .	6.0	0
337	EHMTI-0305. Psychological assessment of patients with chronic refractory headache: a consecutive case series. Journal of Headache and Pain, 2014, 15, .	6.0	0
338	EHMTI-0035. "Cervical pain" study in an Italian tertiary referral headache center. Journal of Headache and Pain, 2014, 15, .	6.0	0
339	EHMTI-0024. The typical duration of migraine aura: a prospective diary-based study. Journal of Headache and Pain, 2014, 15, .	6.0	0
340	EHMTI-0046. The succession of aura symptoms: a prospective diary-based study. Journal of Headache and Pain, 2014, 15, .	6.0	0
341	O001. The Italian Consensus Conference â€œChronic Pain in Neurorehabilitationâ€• Group 29: headache and facial pain. Journal of Headache and Pain, 2015, 16, A132.	6.0	0
342	P007. Inhibition of monoacylglycerol lipase activity modulates the activation of brain structures relevant for migraine pathogenesis. Journal of Headache and Pain, 2015, 16, A165.	6.0	0

#	Article	IF	Citations
343	Rehabilitation from symptomatic drugs overuse: yes, no, may be. Journal of Headache and Pain, 2015, 16, A34.	6.0	0
344	Animal Models of Tension-Type Headache and Trigeminal Autonomic Cephalalgias. Headache, 2015, , 67-82.	0.4	0
345	Polarization of Microglia/Macrophages in Brain Ischaemia: Relevance for Stroke Therapy. Springer Series in Translational Stroke Research, 2017, , 303-328.	0.1	0
346	Board Walk â€“ April 2017. Cephalalgia, 2017, 37, 401-402.	3.9	0
347	The Grand Challenge in Cranial Painâ€”From Migraine to Cranial Neuralgias: Understanding Differences and Similarities to Advance Knowledge and Management. Frontiers in Neurology, 2017, 8, 19.	2.4	0
348	The Treatment of Axial and Foot Dystonia. Biosystems and Biorobotics, 2018, , 171-185.	0.3	0
349	Hormonally Related Headaches. ISGE Series, 2019, , 93-100.	0.2	0
350	Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat. , 2008, , 219-222.		0
351	Headache and the Heart. , 2019, , 1-11.		0
352	Headache and the Heart. , 2020, , 517-527.		0
353	The role of international scientific societies today. Cephalalgia, 2022, , 033310242210920.	3.9	0